Treatment of venous thromboembolism in cancer patients

Seminars in Thrombosis and Hemostasis

Volumn 25, Issue 2, 1999, Pages 245-249

  Levine, Mark N ^a,b   Lee, Agnes Y Y ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b CANCER CARE ONTARIO   (Canada)

Author keywords

Heparin; Low molecular weight heparin; Neoplasm; Venous thromboembolism

Indexed keywords

ENOXAPARIN; HEPARIN; REVIPARIN; WARFARIN;

ANTICOAGULANT THERAPY; BLEEDING; BLOOD FILTER; CANCER; DISEASE ASSOCIATION; DRUG SAFETY; HEPARINIZATION; HUMAN; PRIORITY JOURNAL; REVIEW; THROMBOEMBOLISM; THROMBOSIS PREVENTION; TREATMENT PLANNING;

EID: 0032913034     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-994926     Document Type: Review

References (35)

1. Ginsberg JS. Management of venous thromboembolism, N Engl J Med 1996;335:1816-1828
2. Schwarz RE, Marrero AM, Conlon KC, Burt M. Inferior vena cava filters in cancer patients: Indications and outcomes. J Clin Oncol 1996;14:652-657
3. Levine MN, Raskob GE, Landefeld S, Hirsh J. Hemorrhagic complications of anticoagulant treatment. Chest 1995;108 (Suppl):276-290
4. Levine MN, Hirsh J, Gent M, et al. A randomized trial comparing activated partial thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med 1994;154:49-56
5. Hull RD, Raskob GL, Pineo GF, et al. Subcutaneous low molecular weight heparin compared with continuous intravenous heparin in the treatment of proximal vein thrombosis. N Engl J Med 1992;326:975-982
6. Prandoni P, Lensing AWA, Büller HR, et al. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 1992;339:441-445
7. Simonneau G, Charbonnier B, Décousus H, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep-vein thrombosis. Arch Intern Med 1993;153:1541-1546
8. Feissinger JN, Lopez-Fernandez M, Gatterer E, et al. Once-daily subcutaneous dalteparin, a low-molecular-weight heparin for the initial treatment of acute deep-vein thrombosis. Thromb Haemost 1996;76:195-199
9. Levine M, Gent M, Hirsh J, et al. A comparison of low-molecular-weight hcparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996;334:677-681
10. Koopman MMW, Prandoni P, Piovella F, et al. Treatment of venous thrombosis with intravenous unfractionated hcparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med 1996;334:682-687
11. The Columbus Investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med 1997;337:657-662
12. Hull R, Delmore T, Carter C, et al. Adjusted subcutaneous heparin versus warfarin sodium in the long term treatment of venous thrombosis. N Engl J Med 1982;306:189-194
13. Gitter MJ, Jaeger TM, Peterson TM, Gersh BJ, Silverstein MD. Bleeding and thromboembolism during anticoagulant therapy: A population-based study in Rochester, Minnesota. Mayo Clin Proc 1995;70:725-733
14. Wester JPJ, deValk HW, Nieuwenhuis HK, et al. Risk factors for bleeding during treatment of acute venous thromboembolism. Thromb Haemost 1996;76:682-688
15. Prandoni P. Antithrombotic strategies in patients with cancer. Thromb Haemost 1997;78:141-144
16. Bona RD, Sivjee KY, Hickey AD, Wallace DM, Wajes SB. The efficacy and safety of oral anticoagulation in patients with cancer. Thromh Haemost 1995;74:1055-1058
17. Chan A, Woodruff RK. Complications and failure of anticoagulalion therapy in the treatment of venous thromboembolism in patients with disseminated malignancy. Aust NZ J Med 1992; 22:119-122
18. Clarke-Pearson DL, Synan IS, Creasman WT. Anticoagulation therapy for venous thromboembolism in patients with gynecologic malignancy. Am J Obsiet Gynecol 1983;147:369-375
19. Moore FD, Osteen RT, Karp DD, et al. Anticoagulants, venous thromboembolism, and the cancer patient. Arch Surg 1981; 116:405-407
20. Schulman S, Rhedin AS, Lindmarker P, et al. and the Duration of Anticoagulant Trial Study Group. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thrombocmbolism, N Engl J Med 1995; 332:1661-1665
21. Schulman S, Granqvisl S, Holmström M, et al. and the Duration of Anticoagulation Trial Study Group. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. N Engl J Med 1997;336:393-398
22. Kearon C for the LAFIT Investigators. Two years of warfarin versus placebo following three months of anticoagulation for a first episode of idiopathic venous thromboembolism (VTE). Thromb Haemost 1997;78(Suppl):588(Abstr)
23. Cohen JR, Tenenbaum N, Citron M. Greenfield filter as primary therapy for deep-venous thrombosis and/or pulmonary embolism in patients with cancer. Surgery 1991;109:12-15
24. Decousus H, Leizorovicz A, Parent F, et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep vein thrombosis. N Engl J Med 1998;338:409-415
25. Schiff D, DeAngelis LM. Therapy of venous thromboembolism in patients with brain metastases. Cancer 1994;73:493 498
26. Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997; 337:688-698
27. Zacharski LR, Henderson WG, Rickles FR, et al. Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate. Cancer 1984;53:2045-2052
28. Levine M, Hirsh J, Gent M, et al. Double blind randomized trial of very-low-dose warfarin for the prevention of thromboembolism in stage IV breast cancer. Lancet 1994;343:886 889
29. Maurer LH, Hemdon II JE, Hollis DR, et al. Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited-stage small-cell lung cancer: A Cancer and Leukemia Group B study. J Clin Oncol 1997;15:3378-3387
30. Lebeau B, Chastang C, Brechot J-M, et al. Subcutaneous heparin treatment increases survival in small cell lung cancer. Cancer 1994;74:38-45
31. Lensing AWA, Prins MH, Davidson BL, et al. Treatment of deep venous thrombosis with low-molecular-weighl heparins. A meta-analysis. Arch Intern Med 1995;155:601-607
32. Siragussa S, Cosmi B, Piovella F, et al. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: Results of a meta-analysis. Am J Med 1996;100:269-277
33. Folkman J, Langer R, Linhardt RJ, et al. Angiogenesis inhibition and tumour regression caused by heparin or heparin fragment in the presence of cortisone. Science 1983;221:719-725
34. Norrby K. Heparin and angiogenesis: A low-molecular-weight fraction inhibits and a high-molecular-weight fraction stimulates angiogenesis systemically. Haemostasis 1993;23(Suppl 1): 141-149
35. Lepri A, Benelli LI, Bernardini N, et al. Effect of low-molecular-weight heparin sulphate on angiogenesis in the rat cornea after chemical cauterization. J Ocular Pharmacol 1994;10:273-280